BioVie to present Phase 2 bezisterim Long COVID trial results at ANA 2026 meeting
BIVI•BioVie plans to present Phase 2 findings on bezisterim in Long COVID on Oct. 18 and initial Phase 2 results in early Parkinson’s disease on Oct. 19 at the ANA 2026 meeting in San Diego.
1. Planned presentations
BioVie plans poster presentations on bezisterim’s efficacy and safety in Long COVID and early Parkinson’s disease at the ANA 2026 meeting, scheduled for Oct. 17–20 in San Diego. The company described the findings as data updates, not final trial outcomes.
